We found that the MYD88 expression was significantly higher in high-grade gliomas (p < 0.001 (WHO II vs WHO III), p = 0.0036 (WHO III vs WHO IV), Figures 7A, D–F). Here, MYD88 is linked to central nervous system cancer.